King & Spalding advised Claret Medical in its acquisition by Boston Scientific Corp. (NYSE: BSX) in a transaction consisting of $220 million up front and up to an additional $50 million in milestone payments.
Claret Medical is a privately-held company headquartered in Santa Rosa, Calif. Its portfolio includes the Sentinel Cerebral Embolic Protection System, a medical device that is intended to address the risk of stroke in patients undergoing transcatheter aortic valve replacement (TAVR). The company was founded in 2009. Massachusetts-based Boston Scientific is a global developer, manufacturer and marketer of medical devices.
The King & Spalding team advising Claret was led by San Francisco-based partner Geoff Leonard (San Francisco) and included counsel Jen DePalma (Silicon Valley), senior associate Robert Benson (Atlanta), and associate Katy Alexander (San Francisco/Silicon Valley)
Additional support was provided by partners Elaine Tseng (San Francisco), Preeya Pinto (Washington, D.C.) and Chris Markus (Washington, D.C.) on FDA & regulatory issues; partner Becky Kaufman (Atlanta) on intellectual property issues; partners Ken Raskin (New York) and counsel Mark Kelly (Atlanta) on compensation and benefits questions; counsel Brian Meiners (Washington, D.C.) on antitrust issues; partner Cheryl Sabnis (San Francisco) on labor and employment issues; and partner Wayne Pressgrove (Atlanta), senior associate Robert Beard (Atlanta) and associate Greg Lucas (Atlanta) on tax questions.